As of 2026-09-19, the EV/EBITDA ratio of Rapid Dose Therapeutics Corp (DOSE.CN) is -11.71. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. DOSE.CN's latest enterprise value is 19.59 mil CAD. DOSE.CN's TTM EBITDA according to its financial statements is -1.67 mil CAD. Dividing these 2 quantities gives us the above DOSE.CN EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 4.2x - 6.3x | 5.2x |
| Forward P/E multiples | 4.2x - 6.3x | 5.2x |
| Fair Price | (0.09) - (0.11) | (0.10) |
| Upside | -183.9% - -208.2% | -196.1% |
| Date | EV/EBITDA |
| 2026-09-15 | -11.71 |
| 2026-09-11 | -11.71 |
| 2026-09-10 | -11.71 |
| 2026-09-09 | -12.54 |
| 2026-09-08 | -11.30 |
| 2026-09-04 | -12.95 |
| 2026-09-03 | -12.12 |
| 2026-09-02 | -11.30 |
| 2026-09-01 | -12.12 |
| 2026-08-28 | -12.95 |
| 2026-08-27 | -12.12 |
| 2026-08-26 | -11.30 |
| 2026-08-25 | -12.12 |
| 2026-08-24 | -10.89 |
| 2026-08-20 | -10.48 |
| 2026-08-19 | -11.30 |
| 2026-08-17 | -11.30 |
| 2026-08-14 | -12.54 |
| 2026-08-13 | -12.12 |
| 2026-08-12 | -11.71 |
| 2026-08-11 | -11.30 |
| 2026-08-07 | -10.48 |
| 2026-08-05 | -10.48 |
| 2026-08-04 | -10.48 |
| 2026-07-30 | -10.89 |
| 2026-07-29 | -10.89 |
| 2026-07-27 | -10.89 |
| 2026-07-23 | -10.48 |
| 2026-07-22 | -10.48 |
| 2026-07-21 | -11.71 |
| 2026-07-20 | -11.71 |
| 2026-07-17 | -12.12 |
| 2026-07-16 | -13.36 |
| 2026-07-15 | -12.95 |
| 2026-07-14 | -12.54 |
| 2026-07-13 | -12.54 |
| 2026-07-09 | -12.95 |
| 2026-07-08 | -12.54 |
| 2026-07-07 | -12.54 |
| 2026-07-06 | -12.12 |
| 2026-07-03 | -11.71 |
| 2026-07-02 | -12.12 |
| 2026-06-30 | -11.71 |
| 2026-06-26 | -10.48 |
| 2026-06-25 | -10.06 |
| 2026-06-24 | -11.30 |
| 2026-06-23 | -10.89 |